In this issue of the JCI, Anderson et al. (5) report on the coinfusion of purified CD4 + memory T cells in an MHCmatched, miHA-disparate, T celldepleted murine HSCT model. Their results conclusively show that unpurified CD4 + T cells cause GVHD, while the memory cells (defined here as CD44 + -CD62L -CD4 + T cells) do not. Furthermore, memory CD4 + T cells taken from a donor immunized to chicken γ-globulin (CGG) retain their CGG-specific memory when the recipient of those memory T cells is immunized with CGG. In other words, these CD44 + -CD62L -CD4 + memory T cells remember how to respond to antigens to which they were primed but have "forgotten" how to react to allogeneic miHAs that are the targets of GVHD mediated by unfractionated or naive CD4 + T cells.
Applicability to other strain combinationsThis finding provides some insight on the nature of alloreactivity. In this HSCT model, the CD4 + T cells responsible for GVHD are not in the CD44 + CD62L --CD4 + population (5). As such, the components of the T cell receptor (TCR) repertoire that recognize the miHAs may not be in the CD44 + CD62L -CD4 + mem- Clinical transplantation of hematopoietic stem cells (HSCs) was first successful in 1968 (1, 2) and has provided life-saving therapy for potentially fatal diseases. These include acquired marrow aplasia, inherited dysfunction of hematopoietically-derived elements, and the iatrogenic marrow failure caused by supra-lethal chemo-or radiotherapy in the treatment of neoplasms. The goal of HSCT is stable engraftment of donorderived hematopoietic cells, allowing them to differentiate and function normally, while not causing destruction of host tissues by donor-derived immune cells, resulting in GVHD. The presence of minor histocompatibility antigen (miHA) disparities between allogeneic individuals may induce GVHD, even when donor and recipient are matched at all MHC loci. Immunosuppressive drugs given after HSCT, or T cell depletion of the graft, can decrease the incidence and severity of GVHD (3). However, in the absence of mature T cells, many months are required to re-create an intact T cell immune system (4), leaving the recipient at great risk for opportunistic infection while a new T cell system arises from HSCs and undergoes thymic education ( Figure 1). The ability to infuse donor T cells that protect against infection and provide an antineoplastic effect, while excluding those T cells responsible for damaging normal tissues (observed in Graft-versus-host disease (GVHD) represents a major cause of morbidity and mortality following conventional allogeneic hematopoietic stem cell transplantation (HSCT). A study in mice (see related article on pages 101-108) demonstrates that the selective administration of donor memory CD4 + T cells results in immune reconstitution without GVHD, a result that, if translatable to humans, has important clinical implications for HSCT.